RXC-004 is under clinical development by Redx Pharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect RXC-004’s likelihood of approval (LoA) and phase transition for Metastatic Biliary Tract Cancer took place on 05 Sep 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their RXC-004 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

RXC-004 overview

RXC-004 is under development for the treatment of pancreatic ductal adenocarcinoma, metastatic biliary tract cancer, intrahepatic and extrahepatic cholangiocarcinoma, gallbladder cancer, metastatic colorectal cancer, pancreatic cancer, gastric cancer and biliary tumor. It is administered orally. The drug candidate targets protein cysteine N palmitoyltransferase porcupine of the Wnt pathway. The drug candidate is developed based on Redox Switch technology. It was under development for the treatment of melanoma.

Redx Pharma overview

Redx Pharma, formerly Redx Pharma is a drug discovery and development company that develops early stage and small molecule therapeutics. The company’s major pipeline products include RXC004, RXC007, RXC008, DDR, RXC006/AZD5055, JZP815, among other drug candidates. Its drug products are used for the treatment of pancreatic cancer, idiopathic pulmonary fibrosis (IPF), fibro stenotic crohn’s disease, oncology and fibrosis, and Fibrosis, Cancer-associated fibrosis. Redx Pharma’s redox switch is also used for delivering multiple development candidates over mechanistic approaches in the treatment of cancer. The company conducts research through its facilities in the UK. Redx Pharma is headquartered in Macclesfield, the UK.

Quick View RXC-004 LOA Data

Report Segments
  • Innovator
Drug Name
  • RXC-004
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.